|
|
MicroRNAs and hepatitis viruses |
Gang LI MD , Xiaojia XIONG MM , |
Department of Infectious
Diseases, The Third Affiliated Hospital of Sun-Yat Sen University,
Guangzhou 510630, China; |
|
|
Abstract MicroRNAs (miRNAs) are a class of small RNA molecules. They play a pivotal role in diverse domains such as infection, tumorigenesis, and immune reaction. As key regulators of most genes’ expression, they react at posttranscriptional level. It is increasingly clear that miRNAs are necessary for physiological and pathological processes. In the past few years, investigators gradually brought the concept of miRNA into studies of viral infection, including hepatitis viruses. The hepatitis B and C viruses are common causes of liver disease worldwide. It is very difficult to cure chronic hepatitis due to drug resistance during antivirus therapy. Elucidating the mechanisms of virus-host interactions in hepatitis B and C is very important in diagnosis, prognosis, and therapy. This article reviews the current knowledge of viral hepatitis (B and C type) at the level of miRNA and tries to outline areas of potential studies.
|
Keywords
microRNA
hepatitis B virus
hepatitis C virus
|
Issue Date: 05 September 2009
|
|
|
Lee Y, Kim M, Han J, Yeom K H, Lee S, Baek S H, Kim V N. MicroRNA genes are transcribedby RNA polymerase II. EMBO J, 2004, 23(20): 4051―4060
doi: 10.1038/sj.emboj.7600385
|
|
Lund E, Güttinger S, Calado A, Dahlberg J E, Kutay U. Nuclear export of microRNAprecursors. Science, 2004, 303(5654): 95―98
doi: 10.1126/science.1090599
|
|
Gottwein E, Cullen B R. Viral and cellular microRNAsas determinants of viral pathogenesis and immunity. Cell Host Microbe, 2008, 3(6): 375―387
doi: 10.1016/j.chom.2008.05.002
|
|
Ghosh Z, Mallick B, Chakrabarti J. Cellular versus viral microRNAs in host-virus interaction. Nucleic Acids Res, 2009, 37(4): 1035―1048
doi: 10.1093/nar/gkn1004
|
|
Yu Z, Jian Z, Shen S H, Purisima E, Wang E. Global analysis of microRNAtarget gene expression reveals that miRNA targets are lower expressedin mature mouse and Drosophila tissues than in the embryos. Nucleic Acids Res, 2007, 35(1): 152―164
doi: 10.1093/nar/gkl1032
|
|
Sun R, Fu X, Li Y, Xie Y, Mao Y. Global gene expression analysis revealsreduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics, 2009, 10: 93
doi: 10.1186/1471-2164-10-93
|
|
Schmittgen T D, Lee E J, Jiang J, Sarkar A, Yang L, Elton T S, Chen C. Real-time PCRquantification of precursor and mature microRNA. Methods, 2008, 44(1): 31―38
doi: 10.1016/j.ymeth.2007.09.006
|
|
Rajewsky N. MicroRNAtarget predictions in animals. Nat Genet, 2006, 38(Suppl): S8―13
doi: 10.1038/ng1798
|
|
Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P, Hatzigeorgiou AG. The database of experimentallysupported targets: a functional update of TarBase. Nucleic Acids Res, 2009, 37(Database issue): D155―158
doi: 10.1093/nar/gkn809
|
|
Canales R D, Luo Y, Willey J C, Austermiller B, Barbacioru C C, Boysen C, Hunkapiller K, Jensen R V, Knight C R, Lee K Y, Ma Y, Maqsodi B, Papallo A, Peters E H, Poulter K, Ruppel P L, Samaha R R, Shi L, Yang W, Zhang L, Goodsaid F M. Evaluation of DNA microarrayresults with quantitative gene expression platforms. Nat Biotechnol, 2006, 24: 1115―1122
doi: 10.1038/nbt1236
|
|
Arikawa E, Sun Y, Wang J, Zhou Q, Ning B, Dial SL, Guo L, Yang J. Cross-platform comparison of SYBR Green real-time PCRwith TaqMan PCR, microarrays and other gene expression measurementtechnologies evaluated in the MicroArray Quality Control (MAQC) study. BMC Genomics, 2008, 9: 328
doi: 10.1186/1471-2164-9-328
|
|
Cullen B R. Viruses and microRNAs. Nat Genet, 2006, 38(Suppl): S25―30
doi: 10.1038/ng1793
|
|
Jin W B, Wu F L, Kong D, Guo A G. HBV-encodedmicroRNA candidate and its target. ComputBiol Chem, 2007, 31(2): 124―126
doi: 10.1016/j.compbiolchem.2007.01.005
|
|
Li Z, Zhang S, Huang C, Zhang W, Hu Y, Wei B. MicroRNAomeof splenic macrophages in hypersplenism due to portal hypertensionin hepatitis B virus-related cirrhosis. Exp Biol Med (Maywood), 2008, 233(11): 1454―1461
doi: 10.3181/0711-RM-321
|
|
Gao Y F, Yu L, Wei W, Li J B, Luo Q L, Shen J L. Inhibition of hepatitis B virus gene expression and replication byartificial microRNA. World J Gastroenterol, 2008, 14(29): 4684―4689
doi: 10.3748/wjg.14.4684
|
|
Esau C, Davis S, Murray S F, Yu X X, Pandey S K, Pear M, Watts L, Booten S L, Graham M, McKay R, Subramaniam A, Propp S, Lollo BA, Freier S, Bennett CF, Bhanot S, Monia BP. MiR-122 regulationof lipid metabolism revealed by in vivo antisense targeting. Cell Metab, 2006, 3(2): 87―98
doi: 10.1016/j.cmet.2006.01.005
|
|
Shan Y, Zheng J, Lambrecht R W, Bonkovsky H L. Reciprocal effects of micro-RNA-122 on expression of heme oxygenase-1and hepatitis C virus genes in human hepatocytes. Gastroenterology, 2007, 133(4): 1166―1174
doi: 10.1053/j.gastro.2007.08.002
|
|
Lebanony D, Benjamin H, Gilad S, Ezagouri M, Dov A, Ashkenazi K, Gefen N, Izraeli S, Rechavi G, Pass H, Nonaka D, Li J, Spector Y, Rosenfeld N, Chajut A, Cohen D, Aharonov R, Mansukhani M. Diagnostic assay based onhsa-miR-205 expression distinguishes squamous from nonsquamous non-small-celllung carcinoma. J Clin Oncol, 2009, 27(12): 2030―2037
doi: 10.1200/JCO.2008.19.4134
|
|
Merritt W M, Lin Y G, Han L Y, Kamat A A, Spannuth W A, Schmandt R, Urbauer D, Pennacchio L A, Cheng J F, Nick A M, Deavers M T, Mourad-Zeidan A, Wang H, Mueller P, Lenburg M E, Gray J W, Mok S, Birrer M J, Lopez-Berestein G, Coleman R L, Bar-Eli M, Sood A K. Dicer, Drosha, and outcomesin patients with ovarian cancer. N EnglJ Med, 2008, 359(25): 2641―2650
doi: 10.1056/NEJMoa0803785
|
|
Slack F J, Weidhaas J B. MicroRNA in cancer prognosis. N Engl J Med, 2008, 359(25): 2720―2722
doi: 10.1056/NEJMe0808667
|
|
O'Donnell K A, Wentzel E A, Zeller K I, Dang C V, Mendell J T. c-Myc-regulated microRNAs modulate E2F1expression. Nature, 2005, 435(7043): 839―843
doi: 10.1038/nature03677
|
|
Liu Y, Zhao J J, Wang C M, Li M Y, Han P, Wang L, Cheng Y Q, Zoulim F, Ma X, Xu D P. Altered expression profiles of microRNAsin a stable hepatitis B virus-expressing cell line. Chin Med J (Engl), 2009, 122(1): 10―14
|
|
Ladeiro Y, Couchy G, Balabaud C, Bioulac-Sage P, Pelletier L, Rebouissou S, Zucman-Rossi J. MicroRNAprofiling in hepatocellular tumors is associated with clinical featuresand oncogene/tumor suppressor gene mutations. Hepatology, 2008, 47(6): 1955―1963
doi: 10.1002/hep.22256
|
|
Wong Q W, Lung R W, Law P T, Lai P B, Chan K Y, To K F, Wong N. MicroRNA-223 is commonlyrepressed in hepatocellular carcinoma and potentiates expression ofStathmin1. Gastroenterology, 2008, 135(1): 257―269
doi: 10.1053/j.gastro.2008.04.003
|
|
Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S. Differential microRNA expressionbetween hepatitis B and hepatitis C leading disease progression tohepatocellular carcinoma. Hepatology, 2009, 49(4): 1098―1112
doi: 10.1002/hep.22749
|
|
Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, Nagano H, Nakamori S, Dono K, Tsujimoto M, Nakahara M, Nakao K, Taniguchi N, Monden M. Expressionand prognostic roles of the G1-S modulators in hepatocellular carcinoma:p27 independently predicts the recurrence. Hepatology, 1999, 30(1): 90―99
doi: 10.1002/hep.510300114
|
|
Jing Z, Nan K J, Hu M L. Cell proliferation, apoptosis and the related regulatorsp27, p53 expression in hepatocellular carcinoma. World J Gastroenterol, 2005, 11(13): 1910―1916
|
|
Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes H P, Odenthal M. MicroRNAgene expression profile of hepatitis C virus-associated hepatocellularcarcinoma. Hepatology, 2008, 47(4): 1223―1232
doi: 10.1002/hep.22158
|
|
Gramantieri L, Ferracin M, Fornari F, Veronese A, Sabbioni S, Liu C G, Calin G A, Giovannini C, Ferrazzi E, Grazi G L, Croce C M, Bolondi L, Negrini M. Cyclin G1 is a target ofmiR-122a, a microRNA frequently down-regulated in human hepatocellularcarcinoma. Cancer Res, 2007, 67(13): 6092―6099
doi: 10.1158/0008-5472.CAN-06-4607
|
|
Shehata M A, Nosseir H R, Nagy H M, Farouk G. Cyclindependent kinase inhibitor p27(kip1) expression and subcellular localizationin relation to cell proliferation in hepatocellualr carcinoma. Egypt J Immunol, 2006, 13(1): 115―130
|
|
Fornari F, Gramantieri L, Ferracin M, Veronese A, Sabbioni S, Calin G A, Grazi G L, Giovannini C, Croce C M, Bolondi L, Negrini M. MiR-221 controls CDKN1C/p57and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 2008, 27(43): 5651―5661
doi: 10.1038/onc.2008.178
|
|
Connolly E, Melegari M, Landgraf P, Tchaikovskaya T, Tennant B C, Slagle B L, Rogler L E, Zavolan M, Tuschl T, Rogler C E. Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associatedhepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol, 2008, 173(3): 856―864
doi: 10.2353/ajpath.2008.080096
|
|
Su H, Yang J R, Xu T, Huang J, Xu L, Yuan Y, Zhuang S M. MicroRNA-101, down-regulated in hepatocellularcarcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 2009, 69(3): 1135―1142
doi: 10.1158/0008-5472.CAN-08-2886
|
|
Fleischer B, Schulze-Bergkamen H, Schuchmann M, Weber A, Biesterfeld S, Müller M, Krammer PH, Galle PR. Mcl-1 is ananti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol. 2006, 28(1): 25―32
|
|
Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob S T, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressorgene in human hepatocellular cancer. Gastroenterology, 2007, 133(2): 647―658
doi: 10.1053/j.gastro.2007.05.022
|
|
Jopling C L, Yi M, Lancaster A M, Lemon S M, Sarnow P. Modulation of hepatitis C virus RNA abundanceby a liver-specific MicroRNA. Science, 2005, 309(5740): 1577―1581
doi: 10.1126/science.1113329
|
|
Chang J, Guo J T, Jiang D, Guo H, Taylor J M, Block T M. Liver-specific microRNA miR-122 enhances the replication of hepatitisC virus in nonhepatic cells. J Virol, 2008, 82(16): 8215―8223
doi: 10.1128/JVI.02575-07
|
|
Henke J I, Goergen D, Zheng J, Song Y, Schüttler C G, Fehr C, Jünemann C, Niepmann M. MicroRNA-122 stimulates translationof hepatitis C virus RNA. EMBO J, 2008, 27(24): 3300―3310
doi: 10.1038/emboj.2008.244
|
|
Murakami Y, Aly H H, Tajima A, Inoue I, Shimotohno K. Regulation of the hepatitisC virus genome replication by miR-199a. J Hepatol, 2009, 50(3): 453―460
doi: 10.1016/j.jhep.2008.06.010
|
|
Gao Y F, Yu L, Wei W, Li J B, Luo Q L, Shen J L. Inhibition of hepatitis B virus gene expression and replication byartificial microRNA. World J Gastroenterol, 2008, 14(29): 4684―4689
doi: 10.3748/wjg.14.4684
|
|
Ely A, Naidoo T, Mufamadi S, Crowther C, Arbuthnot P. Expressed anti-HBV primarymicroRNA shuttles inhibit viral replication efficiently in vitro andin vivo. Mol Ther, 2008, 16(6): 1105―1112
doi: 10.1038/mt.2008.82
|
|
Pedersen I M, Cheng G, Wieland S, Volinia S, Croce C M, Chisari F V, David M. Interferonmodulation of cellular microRNAs as an antiviral mechanism. Nature, 2007, 449(7164): 919―922
doi: 10.1038/nature06205
|
|
Sarasin-Filipowicz M, Krol J, Markiewicz I, Heim M H, Filipowicz W. Decreased levels of microRNAmiR-122 in individuals with hepatitis C responding poorly to interferontherapy. Nat Med, 2009, 15(1): 31―33
doi: 10.1038/nm.1902
|
|
Georgantas R W 3rd, Hildreth R, Morisot S, Alder J, Liu C G, Heimfeld S, Calin G A, Croce C M, Civin C I. CD34+ hematopoieticstem-progenitor cell microRNA expression and function: A circuit diagramof differentiation control. Proc Natl AcadSci U S A, 2007, 104(8): 2750―2755
doi: 10.1073/pnas.0610983104
|
|
Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S, Bhatt D, Alder H, Marcucci G, Calin G A, Liu C G, Bloomfield C D, Andreeff M, Croce C M. MicroRNA fingerprints during human megakaryocytopoiesis. Proc Natl Acad Sci U S A, 2006, 103(13): 5078―5083
doi: 10.1073/pnas.0600587103
|
|
Rodriguez A, Vigorito E, Clare S, Warren M V, Couttet P, Soond D R, van Dongen S, Grocock R J, Das P P, Miska E A, Vetrie D, Okkenhaug K, Enright A J, Dougan G, Turner M, Bradley A. Requirement of bic/microRNA-155for normal immune function. Science, 2007, 316(5824): 608―611
doi: 10.1126/science.1139253
|
|
O'Connell R M, Taganov K D, Boldin M P, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophageinflammatory response. Proc Natl Acad SciU S A, 2007, 104(5): 1604―1609
doi: 10.1073/pnas.0610731104
|
|
Ceppi M, Pereira P M, Dunand-Sauthier I, Barras E, Reith W, Santos M A, Pierre P. MicroRNA-155modulates the interleukin-1 signaling pathway in activated human monocyte-deriveddendritic cells. Proc Natl Acad Sci U SA, 2009, 106(8): 2735―2740
doi: 10.1073/pnas.0811073106
|
|
Huang J, Wang F, Argyris E, Chen K, Liang Z, Tian H, Huang W, Squires K, Verlinghieri G, Zhang H. Cellular microRNAs contributeto HIV-1 latency in resting primary CD4+ T lymphocytes. Nat Med, 2007, 13(10): 1241―1247
doi: 10.1038/nm1639
|
|
Jiang J, Lee E J, Schmittgen T D. Increased expression of mi microRNA-155 in Epstein-Barrvirus transformed lymphoblastoid cell lines. Genes Chromosomes Cancer, 2006, 45(1): 103―106
doi: 10.1002/gcc.20264
|
|
Yin Q, McBride J, Fewell C, Lacey M, Wang X, Lin Z, Cameron J, Flemington E K. MicroRNA-155 is an Epstein-Barr virus-induced gene thatmodulates Epstein-Barr virus-regulated gene expression pathways. J Virol, 2008, 82(11): 5295―5306
doi: 10.1128/JVI.02380-07
|
|
Cameron J E, Yin Q, Fewell C, Lacey M, McBride J, Wang X, Lin Z, Schaefer B C, Flemington E K. Epstein-Barr virus latent membrane protein 1 induces cellular MicroRNAmiR-146a, a modulator of lymphocyte signaling pathways. J Virol, 2008, 82(4): 1946―1958
doi: 10.1128/JVI.02136-07
|
|
Gatto G, Rossi A, Rossi D, Kroening S, Bonatti S, Mallardo M. Epstein-Barr virus latent membrane protein 1 trans-activatesmiR-155 transcription through the NF-kappaB pathway. Nucleic Acids Res, 2008, 36(20): 6608―6619
doi: 10.1093/nar/gkn666
|
|
Stern-Ginossar N, Elefant N, Zimmermann A, Wolf D G, Saleh N, Biton M, Horwitz E, Prokocimer Z, Prichard M, Hahn G, Goldman-Wohl D, Greenfield C, Yagel S, Hengel H, Altuvia Y, Margalit H, Mandelboim O. Host immune system gene targeting by a viral miRNA. Science, 2007, 317(5836): 376―381
doi: 10.1126/science.1140956
|
|
Dustin L B, Rice C M. Flying under the radar: theimmunobiology of hepatitis C. Annu RevImmunol, 2007, 25: 71―99
doi: 10.1146/annurev.immunol.25.022106.141602
|
|
Rehermann B, Nascimbeni M. Immunology of hepatitis Bvirus and hepatitis C virus infection. Nat Rev Immunol, 2005, 5(3): 215―229
doi: 10.1038/nri1573
|
|
Shiina M, Rehermann B. Cell culture-produced hepatitisC virus impairs plasmacytoid dendritic cell function. Hepatology, 2008, 47(2): 385―395
doi: 10.1002/hep.21996
|
|
Rigopoulou E I, Abbott W G, Williams R, Naoumov N V. Direct evidence for immunomodulatory properties of ribavirin on T-cellreactivity to hepatitis C virus. AntiviralRes, 2007, 75(1): 36―42
doi: 10.1016/j.antiviral.2006.11.008
|
|
Lu G F, Tang F A, Zheng P Y, Yang P C, Qi Y M. Entecavir up-regulates dendritic cellfunction in patients with chronic hepatitis B. World J Gastroenterol, 2008, 14(10): 1617―1621
doi: 10.3748/wjg.14.1617
|
|
Zheng P Y, Zhang D Y, Lu G F, Yang P C, Qi Y M, Wang B S. Effects of lamivudine on the function of dendritic cells derivedfrom patients with chronic hepatitis B virus infection. World J Gastroenterol, 2007, 13(34): 4641―4645
|
|
Saito T, Gale M Jr. Regulation of innate immunityagainst hepatitis C virus infection. HepatolRes, 2008, 38(2): 115―122
|
|
Ye L, Wang X, Wang S, Wang Y, Song L, Hou W, Zhou L, Li H, Ho W. CD56+ T cellsinhibit hepatitis C virus replication in human hepatocytes. Hepatology, 2009, 49(3): 753―762
doi: 10.1002/hep.22715
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|